Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may track heart drug effectiveness in rare amyloid disease

NCT ID NCT07196839

First seen Oct 31, 2025 · Last updated Jun 12, 2026 · Updated 32 times

Summary

This study measures levels of amyloid proteins in the blood of 50 adults with transthyretin amyloid cardiomyopathy (ATTR-CM) who are taking standard TTR-stabilizing medications like tafamidis or acoramidis. Researchers want to see if these drugs lower amyloid levels over three months, which could lead to a simple blood test to monitor treatment response. Participants must be between 30 and 80 years old with a history of heart failure or elevated heart-related biomarkers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UT Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75248, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.